Literature DB >> 23532923

Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection.

Shirin Ashraf1, Katja Nitschke, Usama M Warshow, Collin R Brooks, Arthur Y Kim, Georg M Lauer, Theresa J Hydes, Matthew E Cramp, Graeme Alexander, Ann-Margaret Little, Robert Thimme, Christoph Neumann-Haefelin, Salim I Khakoo.   

Abstract

UNLABELLED: CD8+ T-cell responses to hepatitis C virus (HCV) are important in generating a successful immune response and spontaneously clearing infection. Human leukocyte antigen (HLA) class I presents viral peptides to CD8+ T cells to permit detection of infected cells, and tapasin is an important component of the peptide loading complex for HLA class I. We sought to determine if tapasin polymorphisms affected the outcome of HCV infection. Patients with resolved or chronic HCV infection were genotyped for the known G/C coding polymorphism in exon 4 of the tapasin gene. In a European, but not a US, Caucasian population, the tapasin G allele was significantly associated with the outcome of HCV infection, being found in 82.5% of resolvers versus 71.3% of persistently infected individuals (P = 0.02, odds ratio [OR] = 1.90 95% confidence interval [CI] = 1.11-3.23). This was more marked at the HLA-B locus at which heterozygosity of both tapasin and HLA-B was protective (P < 0.03). Individuals with an HLA-B allele with an aspartate at residue 114 and the tapasin G allele were more likely to spontaneously resolve HCV infection (P < 0.00003, OR = 3.2 95% CI = 1.6-6.6). Additionally, individuals with chronic HCV and the combination of an HLA-B allele with an aspartate at residue 114 and the tapasin G allele also had stronger CD8+ T-cell responses (P = 0.02, OR = 2.58, 95% CI-1.05-6.5).
CONCLUSION: Tapasin alleles contribute to the outcome of HCV infection by synergizing with polymorphisms at HLA-B in a population-specific manner. This polymorphism may be relevant for peptide vaccination strategies against HCV infection.
© 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23532923      PMCID: PMC3759612          DOI: 10.1002/hep.26415

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  HLA-B polymorphism affects interactions with multiple endoplasmic reticulum proteins.

Authors:  H R Turnquist; H J Thomas; K R Prilliman; C T Lutz; W H Hildebrand; J C Solheim
Journal:  Eur J Immunol       Date:  2000-10       Impact factor: 5.532

Review 2.  The cell biology of MHC class I antigen presentation.

Authors:  A Williams; C A Peh; T Elliott
Journal:  Tissue Antigens       Date:  2002-01

3.  Optimization of the MHC class I peptide cargo is dependent on tapasin.

Authors:  Anthony P Williams; Chen Au Peh; Anthony W Purcell; James McCluskey; Tim Elliott
Journal:  Immunity       Date:  2002-04       Impact factor: 31.745

4.  Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC.

Authors:  Tariq Ahmad; Matt Neville; Sara E Marshall; Alessandro Armuzzi; Kim Mulcahy-Hawes; Jonathan Crawshaw; Hiroe Sato; Khoon-Lin Ling; Martin Barnardo; Sue Goldthorpe; Robert Walton; Mike Bunce; Derek P Jewell; Ken I Welsh
Journal:  Hum Mol Genet       Date:  2003-03-15       Impact factor: 6.150

5.  Sequencing protocols for detection of HLA class I polymorphism.

Authors:  Paul P J Dunn; Steven T Cox; Ann-Margaret Little
Journal:  Methods Mol Biol       Date:  2003

6.  A single polymorphic residue within the peptide-binding cleft of MHC class I molecules determines spectrum of tapasin dependence.

Authors:  Boyoun Park; Sungwook Lee; Euijae Kim; Kwangseog Ahn
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

7.  Identification of novel Tapasin polymorphisms and linkage disequilibrium to MHC class I alleles.

Authors:  A P Williams; S Bevan; M Bunce; R Houlston; K I Welsh; T Elliott
Journal:  Immunogenetics       Date:  2000-11       Impact factor: 2.846

8.  HLA-Cw*04 and hepatitis C virus persistence.

Authors:  Chloe L Thio; Xiaojiang Gao; James J Goedert; David Vlahov; Kenrad E Nelson; Margaret W Hilgartner; Stephen J O'Brien; Peter Karacki; Jacquie Astemborski; Mary Carrington; David L Thomas
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection.

Authors:  Salim I Khakoo; Chloe L Thio; Maureen P Martin; Collin R Brooks; Xiaojiang Gao; Jacquie Astemborski; Jie Cheng; James J Goedert; David Vlahov; Margaret Hilgartner; Steven Cox; Ann-Margeret Little; Graeme J Alexander; Matthew E Cramp; Stephen J O'Brien; William M C Rosenberg; David L Thomas; Mary Carrington
Journal:  Science       Date:  2004-08-06       Impact factor: 47.728

10.  Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source.

Authors:  Susan M McKiernan; Richard Hagan; Michael Curry; George S A McDonald; Alan Kelly; Niamh Nolan; Anne Walsh; John Hegarty; Emer Lawlor; Dermot Kelleher
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

View more
  11 in total

1.  Genetics of spontaneous clearance of hepatitis C virus infection: a complex topic with much to learn.

Authors:  Jason Grebely; Gregory J Dore; Arthur Y Kim; Andrew Lloyd; Naglaa H Shoukry; Maria Prins; Kimberly Page
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

2.  A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A(*)24 Allotypes.

Authors:  Soumya Badrinath; Heike Kunze-Schumacher; Rainer Blasczyk; Trevor Huyton; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-12-04       Impact factor: 4.818

3.  Association of polymorphisms in HLA antigen presentation-related genes with the outcomes of HCV infection.

Authors:  Peng Huang; Yuanyuan Zhang; Xiaomei Lu; Yin Xu; Jie Wang; Yun Zhang; Rongbin Yu; Jing Su
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 4.  Protective immunity against hepatitis C: many shades of gray.

Authors:  Mohamed S Abdel-Hakeem; Naglaa H Shoukry
Journal:  Front Immunol       Date:  2014-06-16       Impact factor: 7.561

5.  Genetic variants in antigen presentation-related genes influence susceptibility to hepatitis C virus and viral clearance: a case control study.

Authors:  Peng Huang; Li Dong; Xiaomei Lu; Yuanyuan Zhang; Hongbo Chen; Jie Wang; Yun Zhang; Jing Su; Rongbin Yu
Journal:  BMC Infect Dis       Date:  2014-12-21       Impact factor: 3.090

Review 6.  Review article: genetic factors that modify the outcome of viral hepatitis.

Authors:  A F Stättermayer; T Scherzer; S Beinhardt; K Rutter; H Hofer; P Ferenci
Journal:  Aliment Pharmacol Ther       Date:  2014-03-24       Impact factor: 8.171

7.  Structural mechanism of tapasin-mediated MHC-I peptide loading in antigen presentation.

Authors:  Jiansheng Jiang; Daniel K Taylor; Ellen J Kim; Lisa F Boyd; Javeed Ahmad; Michael G Mage; Hau V Truong; Claire H Woodward; Nikolaos G Sgourakis; Peter Cresswell; David H Margulies; Kannan Natarajan
Journal:  Nat Commun       Date:  2022-09-17       Impact factor: 17.694

8.  The interaction of genetic determinants in the outcome of HCV infection: evidence for discrete immunological pathways.

Authors:  T J Hydes; B Moesker; J A Traherne; S Ashraf; G J Alexander; B D Dimitrov; C H Woelk; J Trowsdale; S I Khakoo
Journal:  Tissue Antigens       Date:  2015-10

9.  STAT4-associated natural killer cell tolerance following liver transplantation.

Authors:  K M Jamil; T J Hydes; K S Cheent; S A Cassidy; J A Traherne; J Jayaraman; J Trowsdale; G J Alexander; A-M Little; H McFarlane; M A Heneghan; M A Purbhoo; S I Khakoo
Journal:  Gut       Date:  2016-02-17       Impact factor: 23.059

Review 10.  Current Challenges in Vaccinology.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Peter Palese; Gregory A Poland
Journal:  Front Immunol       Date:  2020-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.